Zobrazeno 1 - 10
of 263
pro vyhledávání: '"J. B. A. G. HAANEN"'
Autor:
J. S. W. Borgers, F. H. Burgers, E. M. Terveer, M. E. van Leerdam, C. M. Korse, R. Kessels, C. C. Flohil, C. U. Blank, T. N. Schumacher, M. van Dijk, J. G. E. Henderickx, J. J. Keller, H. W. Verspaget, E. J. Kuijper, J. B. A. G. Haanen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The gut microbiome plays an important role in immune modulation. Specifically, presence or absence of certain gut bacterial taxa has been associated with better antitumor immune responses. Furthermore, in trials using fecal microb
Externí odkaz:
https://doaj.org/article/6bd20975d8584eeab94f604ed9b0c810
Autor:
E. E. A. P. Mulder, K. de Joode, S. Litière, A. J. ten Tije, K. P. M. Suijkerbuijk, M. J. Boers-Sonderen, G. A. P. Hospers, J. W. B. de Groot, A. J. M. van den Eertwegh, M. J. B. Aarts, D. Piersma, R. S. van Rijn, E. Kapiteijn, G. Vreugdenhil, F. W. P. J. van den Berkmortel, E. Oomen-de Hoop, M. G. Franken, B. Ryll, P. Rutkowski, S. Sleijfer, J. B. A. G. Haanen, A. A. M. van der Veldt
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two yea
Externí odkaz:
https://doaj.org/article/1258e8cfb799432884b62bfb054d74e9
Autor:
B. M. Aarts, E. G. Klompenhouwer, S. L. Rice, F. Imani, T. Baetens, A. Bex, S. Horenblas, M. Kok, J. B. A. G. Haanen, R. G. H. Beets-Tan, F. M. Gómez
Publikováno v:
Insights into Imaging, Vol 10, Iss 1, Pp 1-12 (2019)
Abstract Cancer cells can escape the immune system by different mechanisms. The evasion of cancer cells from immune surveillance is prevented by immune checkpoint inhibitors, allowing the patient’s own immune system to attack their cancer. Immune c
Externí odkaz:
https://doaj.org/article/638397b77173451b929f42438379e076
Autor:
Stefanie L. Groenland, J. M. Janssen, C. M. Nijenhuis, N. de Vries, H. Rosing, S. Wilgenhof, J. V. van Thienen, J. B. A. G. Haanen, C. U. Blank, J. H. Beijnen, A. D. R. Huitema, N. Steeghs
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:447-456
Publikováno v:
Leerboek oncologieverpleegkunde ISBN: 9789036826440
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea93bd101a39634709d21b0d378ababc
https://doi.org/10.1007/978-90-368-2645-7_16
https://doi.org/10.1007/978-90-368-2645-7_16
Publikováno v:
Leerboek oncologie ISBN: 9789036824484
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aac8fd8c99d84e983e619d2577e60fac
https://doi.org/10.1007/978-90-368-2449-1_24
https://doi.org/10.1007/978-90-368-2449-1_24
Publikováno v:
Leerboek oncologie ISBN: 9789036824484
Leerboek oncologie ISBN: 9789036804417
Leerboek oncologie
Leerboek oncologie ISBN: 9789036804417
Leerboek oncologie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d03d035a2b6607ef90da68fccbd11e1
https://doi.org/10.1007/978-90-368-2449-1_11
https://doi.org/10.1007/978-90-368-2449-1_11
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 160
Immunotherapy with checkpoint inhibitors is an effective strategy for several cancers. In some patients long-term remissions are seen. However, enhancement of the immune response can be accompanied by immune-related adverse events (irAEs). These pati
Autor:
C M, Nijenhuis, A D R, Huitema, C, Blank, J B A G, Haanen, J V, van Thienen, H, Rosing, J H M, Schellens, J H, Beijnen
Publikováno v:
Journal of clinical pharmacology. 57(1)
Autor:
Axel Bex, C. J.C. van den Bogaard, J. J. Sein, J. B. A. G. Haanen, W. van de Kasteele, Trees A. M. Dellemijn, Florry A. Vyth-Dreese, W. J. Nooijen, G. C. De Gast
Publikováno v:
Clinical and Experimental Immunology. 162:447-459
Summary Natural killer T (NK T) cells play a central role as intermediates between innate and adaptive immune responses important to induce anti-tumour reactivity in cancer patients. In two of 14 renal cell carcinoma (RCC) patients, treated with inte